Tag: HEOR

Purchasing Medical Innovation: The Implications for the Medical Device Industry
October 13, 2015 - 3:17 pm, by
In an earlier blog, we reviewed the recent book by one of Avalon’s directors, James Robinson. Robinson’s book, entitled “Purchasing Medical Innovation: The Right Technology, for the Right Patient, at the Right Price” seeks to unpack the often precarious relationships among medical device makers, the purchasers of those devices, the insurers, who are often the...
Controlling the Costs of Clinical Laboratory Testing in Medical Practice
August 20, 2015 - 3:08 pm, by
Today’s clinical laboratory can do much more than you think. Advances in molecular diagnostics, genetics and biomarkers have ushered in a new era of clinical laboratory capabilities. Along with these advances, however, are higher laboratory expenditures. The U.S. Medicare program spent $6.5 billion annually on laboratory in 2006. By 2010, the program was spending $8.2...
The New Era of Cost Control in Healthcare: What Should you look for in a Health Economics and Outcomes Research Consultant?
May 12, 2015 - 2:58 pm, by
In recent years, there has been a small but measurable slowdown in the rate of increase in health expenditures, both here in the U.S. and abroad. The slowdown is largely attributable to a higher level of commitment on the part of payers to increase enrollee cost sharing and control access to high cost treatments.[1-3] If...
Paying for Specialty Pharmaceuticals: The Case of Injectable Oncology Drugs
April 28, 2015 - 2:51 pm, by
According to the American Cancer Society, the financial costs of cancer are high for both the person with cancer and for society as a whole. The National Institutes of Health (NIH) estimated the 2009 overall annual costs of cancer in the U.S. to be $216.6 billion, consisting of $86.6 billion in direct costs and $130...
Integration of Novel Diagnostics into Clinical Practice
February 28, 2015 - 2:46 pm, by
Similar to drug and device markets, a critical part of the success of novel diagnostics is educating providers on clinical and therapeutic utility. However, unlike pharmaceutical drugs, the ordering of a diagnostic test does not necessarily imply a change in provider behavior or a change in treatment strategy. It’s a bit like whether a tree...
The State of the Union and Innovation in Molecular Diagnostics
January 22, 2015 - 11:41 am, by
During the U.S. “State of the Union” address this past week, President Obama devoted some time to emphasizing the importance of “personalized medicine,” referring to the rapid pace of innovation and the high expectations for the role molecular diagnostics in the U.S. health care system: “I want the country that eliminated polio and mapped the...
The Costs of Antibiotic Resistance and the Need for Antibiotic Stewardship
August 18, 2014 - 1:45 pm, by
After suffering from a nasty cold for more than a few days, many of us think about checking in with our doctor just to be sure that it’s not something worse. The result on those visits is, all too often, a simple confirmation of what you already knew: you have a cold. You’ll get better....
The Evolving Role of the New Generation of Molecular Diagnostics in U.S. Health Markets: Development, Clinical Integration, and Evaluation
July 6, 2014 - 1:35 pm, by
The high cost of adverse events has been estimated to be at least US$177 billion per year in the U.S., and prescription drugs overall have efficacy only approximately 50% of the time, representing a potential waste of approximately $350 billion of the worldwide $700 billion or more drug spending (Miller et al., 2011). The wide...
The Economics of Ovarian Cancer Diagnosis
February 6, 2014 - 1:09 pm, by
According to estimates from the World Health Organization, 8.3 million people worldwide died from cancer and other neoplasms in 2008—about 14% of all deaths. In the same year, the overall costs of cancer care in the United States amounted to $228.1 billion– $93.2 billion direct medical costs, $18.8 billion in indirect morbidity costs, and $116.1...
Value-Based Purchasing for Hospital Services in the U.S.
January 15, 2014 - 1:05 pm, by
The Center for Medicare and Medicaid Services (CMS) Value-Based Purchasing (VBP) program is an incentive-based repayment plan linked to the quality of care hospitals provide to Medicare patients. With VBP, hospitals are held accountable for both the quality and cost of their services, and must reach specified performance measures to be rewarded. CMS continues to...
Avalon Health Economics LLC